Definium says its LSD drug notched another Phase 3 win in anxiety disorder

Definium Therapeutics reported results Monday for its third Phase 3 readout this year on its oral LSD candidate, called DT120, and is gearing up for an FDA submission. The company’s late-stage data are from a ...